Rigel Pharmaceuticals (RIGL) Competitors $19.56 -0.01 (-0.05%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RIGL vs. INVA, NVAX, OPK, GERN, MYGN, ZBIO, VSTM, XOMA, VNDA, and EBSShould you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Innoviva (INVA), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Myriad Genetics (MYGN), Zenas Biopharma (ZBIO), Verastem (VSTM), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), and Emergent BioSolutions (EBS). These companies are all part of the "biotechnology" industry. Rigel Pharmaceuticals vs. Innoviva Novavax OPKO Health Geron Myriad Genetics Zenas Biopharma Verastem XOMA Vanda Pharmaceuticals Emergent BioSolutions Rigel Pharmaceuticals (NASDAQ:RIGL) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations. Is RIGL or INVA more profitable? Innoviva has a net margin of 18.31% compared to Rigel Pharmaceuticals' net margin of 2.46%. Innoviva's return on equity of 20.84% beat Rigel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rigel Pharmaceuticals2.46% -14.80% 3.03% Innoviva 18.31%20.84%11.38% Which has preferable earnings & valuation, RIGL or INVA? Innoviva has higher revenue and earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRigel Pharmaceuticals$179.28M1.95-$25.09M$0.9420.81Innoviva$358.71M3.27$179.72M$0.1998.37 Does the MarketBeat Community prefer RIGL or INVA? Rigel Pharmaceuticals received 161 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 68.98% of users gave Rigel Pharmaceuticals an outperform vote while only 57.52% of users gave Innoviva an outperform vote. CompanyUnderperformOutperformRigel PharmaceuticalsOutperform Votes46768.98% Underperform Votes21031.02% InnovivaOutperform Votes30657.52% Underperform Votes22642.48% Do institutionals and insiders hold more shares of RIGL or INVA? 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 9.0% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 2.3% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate RIGL or INVA? Rigel Pharmaceuticals currently has a consensus price target of $36.80, indicating a potential upside of 88.14%. Innoviva has a consensus price target of $55.00, indicating a potential upside of 194.28%. Given Innoviva's stronger consensus rating and higher probable upside, analysts plainly believe Innoviva is more favorable than Rigel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rigel Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Innoviva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, RIGL or INVA? Rigel Pharmaceuticals has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Does the media prefer RIGL or INVA? In the previous week, Rigel Pharmaceuticals and Rigel Pharmaceuticals both had 4 articles in the media. Innoviva's average media sentiment score of 1.31 beat Rigel Pharmaceuticals' score of 1.10 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryInnoviva beats Rigel Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RIGL vs. The Competition Export to ExcelMetricRigel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$349.48M$6.89B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio139.727.4422.4418.48Price / Sales1.95242.66394.66103.91Price / CashN/A65.8538.1834.62Price / Book-11.936.516.774.25Net Income-$25.09M$143.21M$3.22B$248.23M7 Day Performance7.71%3.97%3.09%3.29%1 Month Performance9.40%0.37%-0.14%2.43%1 Year Performance86.29%2.59%17.98%5.54% Rigel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RIGLRigel Pharmaceuticals2.5977 of 5 stars$19.56-0.1%$36.80+88.1%+86.3%$349.48M$179.28M139.72160Upcoming EarningsPositive NewsGap DownINVAInnoviva4.2174 of 5 stars$18.28+0.1%$55.00+200.9%+23.7%$1.15B$358.71M26.49100Upcoming EarningsAnalyst UpgradeNews CoveragePositive NewsNVAXNovavax3.6274 of 5 stars$6.01+0.2%$18.00+199.5%+54.0%$966.67M$682.16M-2.661,990OPKOPKO Health4.4856 of 5 stars$1.37-3.5%$2.75+100.7%+13.1%$920.02M$713.14M-7.214,200Earnings ReportShort Interest ↓News CoverageGERNGeron3.9973 of 5 stars$1.35+6.3%$5.75+325.9%-64.1%$859.83M$76.99M-4.2270Upcoming EarningsMYGNMyriad Genetics4.1007 of 5 stars$7.40-3.1%$20.61+178.5%-62.1%$682.07M$837.60M-5.692,600Upcoming EarningsHigh Trading VolumeZBIOZenas BiopharmaN/A$9.75+9.3%$40.00+310.3%N/A$407.54M$5M-2.75N/AGap DownVSTMVerastem3.1278 of 5 stars$6.21+8.2%$13.89+123.7%-24.9%$319.75M$10M-1.9550Upcoming EarningsAnalyst RevisionXOMAXOMA4.0289 of 5 stars$22.09+4.3%$59.67+170.1%-5.1%$264.04M$10.22M-6.3510Upcoming EarningsPositive NewsVNDAVanda Pharmaceuticals4.1104 of 5 stars$4.29-0.9%$16.50+284.6%-5.3%$250.18M$198.77M-13.41290Upcoming EarningsShort Interest ↑Positive NewsEBSEmergent BioSolutions4.0215 of 5 stars$4.55-1.5%$14.33+215.0%+183.5%$247.23M$1.01B-1.112,420Upcoming EarningsGap Down Related Companies and Tools Related Companies Innoviva Alternatives Novavax Alternatives OPKO Health Alternatives Geron Alternatives Myriad Genetics Alternatives Zenas Biopharma Alternatives Verastem Alternatives XOMA Alternatives Vanda Pharmaceuticals Alternatives Emergent BioSolutions Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RIGL) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RIGL Stock Free RIGL Stock Alerts